Tracking premenstrual exacerbation (PME) of depression in a prospective clinical cohort: the TIDE study protocol

The TIDE study protocol outlines a prospective clinical cohort investigation designed to assess the feasibility of daily symptom tracking, estimate the prevalence of premenstrual exacerbation (PME) in women with depression, and explore its association with other hormone-related mood symptoms.

The Gist

Imagine your mood as a garden. For most people, the weather in this garden changes slowly and predictably. But for some women with depression, there is a specific time of the month when a sudden, heavy storm rolls in, making the garden much harder to tend to. This paper is about a new study called TIDE that wants to learn exactly how these storms happen and how to track them.

Here is a simple breakdown of what the researchers are doing, using everyday comparisons:

The Problem: The "Hidden" Storm

We know that about 60% of women with depression feel their symptoms get worse right before their period. Scientists call this Premenstrual Exacerbation (PME).

Think of it like this: If you have a chronic backache, you might feel it all year round. But for some, that backache turns into a sharp, unbearable pain for a week every month.

• The Issue: Most doctors and patients only look at the "average" pain over the whole month. They might miss the fact that the pain spikes dramatically at a specific time.
• The Mistake: Past studies asked people to look back at the last month and guess, "Did I feel worse before my period?" The paper says this is like trying to remember exactly what you ate for breakfast three weeks ago. Your memory is often unreliable, and you might guess wrong.

The Solution: The "Daily Weather Report"

The TIDE study wants to stop guessing and start measuring. They are recruiting 60 women who are currently being treated for depression and have regular periods.

Instead of asking for a memory, they are asking the women to keep a daily diary (like a weather log) for two full months.

• The Tool: Every night, the women will fill out a short survey on their phone about how they feel.
• The Goal: To see if there is a clear pattern where their mood drops significantly in the week before their period starts, compared to the rest of the month.

The Three Big Questions

The study is trying to answer three main questions:

1. Is it doable? Can women actually stick to filling out a diary every day for two months without getting tired of it? (The researchers hope the answer is yes).
2. How common is it? Now that we are looking closely with a "magnifying glass" (daily tracking) instead of a blurry pair of glasses (retrospective memory), how many women actually have this premenstrual spike?
3. Is there a pattern? Do women who have these monthly storms also tend to have had trouble with mood changes during other big hormonal times, like pregnancy or while taking birth control pills?

The "Gift" to Participants

One of the coolest parts of this study is what happens at the end.

• The Report: After the women finish their two months of tracking, the researchers will give them a personalized report. Think of this as a customized map of their own emotional weather.
• The Insight: The map will show, "Hey, look! Every time your period was coming, your sadness and anxiety went up."
• The Use: The study hopes that seeing this map will help women understand their own bodies better. It might help them tell their doctors, "I know I feel worse in the week before my period, so let's plan for that."

What the Paper Does Not Say

It is important to stick to what the paper actually claims:

• It is not a treatment yet: This study is just about tracking and understanding. It is not testing new medicines or therapies.
• It is not a diagnosis tool for everyone yet: The study is testing if this daily tracking method works well. It hasn't proven yet that this method should replace current ways of diagnosing depression.
• It is not about fixing the problem immediately: The paper says that once we understand the problem better, then we might be able to try new treatments (like adjusting medication doses during the stormy week), but that is a future step, not something happening in this specific study.

Summary

The TIDE study is like setting up a high-tech weather station in the lives of women with depression. Instead of guessing if a storm is coming, they want to record the rain every single day to prove that the storm exists, see how often it happens, and give the women a clear picture of their own unique weather patterns.

Technical Summary

1. Problem Statement

While there is established evidence that menstrual cycle fluctuations affect mood, research specifically focusing on women with existing depressive disorders remains scarce.

• Premenstrual Exacerbation (PME): Approximately 60% of women with depression experience a worsening of symptoms in the premenstrual week. However, PME is distinct from Premenstrual Dysphoric Disorder (PMDD), as PMDD requires symptoms to be absent outside the premenstrual window, whereas PME involves continuous symptoms that intensify cyclically.
• Diagnostic Limitations: Current diagnostic guidelines for PME are non-existent. Existing prevalence estimates rely heavily on retrospective self-reporting, which has been proven unreliable (often overestimating prevalence by 2–3 times compared to prospective tracking).
• Clinical Gap: There is a lack of prospective, daily tracking data in clinical cohorts to determine the true prevalence of PME, assess the feasibility of daily monitoring, and understand the relationship between PME and other hormone-related mood disturbances (e.g., peripartum depression, hormonal contraceptive side effects).

2. Methodology

The TIDE (Tracking premenstrual exacerbation of depression) study is a prospective observational cohort study designed to address these gaps.

• Study Design: Prospective daily diary study over two consecutive menstrual cycles.
• Participants:
  • Target Sample: 60 female participants aged 18–45.
  • Inclusion Criteria: Diagnosed with unipolar depression, currently in outpatient treatment, regular natural menstrual cycles, not using hormonal contraceptives.
  • Exclusion Criteria: Bipolar disorder (due to unique manic/psychotic PME presentations), pregnancy/breastfeeding (<1 year), inability to use a smartphone, or insufficient Dutch language proficiency.
• Data Collection Instruments:
  1. Baseline Questionnaire: Demographics, psychiatric history, trauma, social support, and retrospective history of hormonal contraceptive side effects and peripartum depression.
  2. Retrospective Screening: Premenstrual Symptom Screening Tool (PSST) administered on Cycle Day 1 and Day 10 to compare retrospective vs. prospective data.
  3. Daily Diaries (Primary Data): Sent via smartphone daily. Items are adapted from the PHQ-9 (depression) and Daily Record of Severity of Problems (DRSP) (PMDD), focusing on core emotional and physical symptoms while minimizing redundancy.
  4. Study Evaluation Questionnaire: Administered post-study to assess feasibility, burden, and the clinical utility of the generated symptom reports.
• Analysis Plan:
  • Feasibility: Assessed via dropout rates, missing data proportion, and participant feedback.
  • Prevalence of PME: Determined using three distinct scoring methods to compare discrepancies:
    1. Effect Size Method: Calculates the difference between luteal and follicular phase means divided by the standard deviation of the full cycle (Cutoff: ≥1.0).
    2. C-PASS Criteria: Adapted from PMDD diagnostic criteria (focusing on symptom clearance in the follicular phase), though modified due to the shortened diary item list.
    3. PACTS (Phase-Aligned Cycle Time Scaling): A continuous time-scaling method to analyze symptom severity relative to menses onset without rigid phase categorization.
  • Associations: Binomial linear regression to correlate PME status with retrospective reports of peripartum depression and hormonal contraceptive adverse effects, controlling for confounders (trauma, SES, etc.).

3. Key Contributions

• Methodological Rigor: This is one of the few studies to utilize prospective daily tracking (the "gold standard") rather than retrospective recall to diagnose PME in a clinically depressed cohort.
• Comparative Scoring: It introduces a multi-method approach (Effect Size, C-PASS, and PACTS) to determine the most robust detection method for PME, addressing the lack of a standardized clinical threshold.
• Participant-Centric Feedback Loop: The study includes a unique intervention where participants receive a personalized symptom report visualizing their own cycle data. This allows the researchers to evaluate the clinical relevance and utility of such feedback for patient self-management.
• Transdiagnostic Framework: By examining the overlap between PME, peripartum depression, and hormonal contraceptive sensitivity, the study supports the "hormonal sensitivity" hypothesis, suggesting PME may be a marker for broader vulnerability to sex hormone fluctuations.

4. Results

Note: As this is a study protocol posted as a preprint, empirical results (prevalence rates, statistical significance) have not yet been generated. The "Results" section of the paper describes the expected outcomes and the methodology for reporting future findings.

• Expected Findings: The authors anticipate that daily tracking will reveal a more accurate (likely lower) prevalence of PME compared to retrospective estimates.
• Feasibility Hypothesis: The study expects that providing participants with a visual symptom report will increase their insight into symptom trajectories and be perceived as clinically significant.
• Adherence Strategy: To mitigate the risk of missing data during severe premenstrual weeks (when participants feel worst), the protocol employs personal rapport building (dedicated contact person) and emphasizes the importance of completing diaries even during low-mood periods to ensure data integrity.

5. Significance

• Clinical Practice: Establishing a reliable detection method for PME could lead to personalized treatment strategies, such as adjusting antidepressant dosages during the luteal phase or introducing specific hormonal interventions, which are currently not standard guidelines.
• Patient Empowerment: Validating PME through daily tracking can help patients recognize cyclical patterns, reducing self-blame and improving communication with healthcare providers and support networks.
• Future Research: The study aims to lay the groundwork for interventional trials targeting PME specifically, moving beyond the "one-size-fits-all" approach to depression treatment.
• Open Science: The protocol, materials, and future analysis code are made available via OSF, promoting transparency and reproducibility in the field of menstrual cycle research.